Check and Double Check – the Cochrane review by Storebo et al. (2015) is indeed flawed
Literature
2016) Trust, but verify. The errors and misinterpretations in the Cochrane analysis by O. J. Storebo and colleagues on the efficacy and safety of methylphenidate for the treatment of children and adolescents with ADHD. Zeitschrift für Kinder und Jugendpsychiatrie und Psychotherapie. doi: 10.1024/1422-4917/a000433
(1985). Methylphenidate and cognitive therapy: A comparison of treatment approaches with hyperactive boys. Journal of Abnormal Child Psychology, 13, 69–87.
(2009). Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 48(9), 884–893.
(2016). Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. JAMA: the Journal of the American Medical Association, 315(18), 1997–2008. http://doi.org/10.1001/jama.2016.5453.
(2013) European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. European Neuropsychopharmacology 23(10), .
(2007) The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder. Biological Psychiatry 62(9): 954–62.
(1981) Differential effects of parent training and stimulant medication with hyperactives: a progress report. Journal of the American Academy of Child and Adolescent Psychiatry, 20, 135–147.
(2006). Efficacy and safety of immediate-release methylphenidate treatment for pre-schoolers with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 45(11), 1284–1293.
, (2016). Response to: The evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder is in fact flawed. European Child and Adolescent Psychiatry. http://doi.org/10.1007/s00787-016-0856-z.
(1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1073–1086.
, (2015). Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews, Issue 11. Art. No.: CD009885. DOI: 10.1002/14651858.CD009885.pub2.
, (